《大行報告》瑞信升中生製藥(01177.HK)目標價至9.05元評級「中性」
瑞信發表報告指,中生製藥(01177.HK)肺癌藥物安羅替尼(Anlotinib)使用指引擴大有助開啟市場潛力,有望成為約2萬新肉瘤病患的標準用藥,料銷售最高可達4.5億元人民幣。加上中生製藥為該產品提交多個申請,相信將來可進一步擴大市場潛力。另外,他達拉非片(Tadalafil)及替格瑞洛片(Ticagrelor)已通過生體相等性(BE)試驗,相信推出後在銷售高峰期,可搶佔內地之20%-30%市場份額。
該行上調中生製孳2020年及2021年收入及盈利預測,升2020年收入及盈利預測0.67%及0.6%,2021年收入及盈利預測則上調1.43%及1.34%。料今年上半年純利可升逾10%,管理層亦指引今年全年盈利增長20%-25%。目標價自8.26元上調至9.05元,評級維持「中性」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.